Thierry Bernardi is the founder of BioFilm Control as well as the inventor of the BioFilm Ring Test®. He has co-authored 8 peer reviewed publications and 7 patent applications using the BioFilm Ring Test® technology. Prior to founding BioFilm Control, he held several technical, general management...

Dr. Bleasdale is the physician lead for antimicrobial stewardship and infection prevention at the University of Illinois Hospital and Health Sciences System (UIH) and is a leader in related research.  In administrative roles, she directs initiatives to reduce HAIs, infections with multidrug...

Professor Mark Bradley heads the EPSRC and MRC Centre for Doctoral Training in Optical Medical Imaging and is an ERC Advanced Grant holder.Mark has a demonstrated capacity to work, publish and patent across the boundaries with a focus on the application of the tools of chemistry with the synthesis...

Colin Broom joined Nabriva Therapeutics in August 2014. Over the past 30 years, he has been involved in all stages of drug development and commercialization. Most recently, he served as Chief Scientific Officer at ViroPharma, Inc., (now Shire). Previous positions have included a range of leadership ...

Dr. Manu Chaudhary serves as the Joint Managing Director cum Director Research at Venus Remedies Limited, India. She has over 25 years of experience in the discovery and development of anti-infectives, anti-cancer and pain management products. She is a renowned expert in pharmaceutical research and ...

Lisa Davidson, MD, serves as the Medical Director of the Atrium Health Antimicrobial Support Network and as an attending Faculty Physician in the Infectious Disease Division at Carolinas Medical Center. She graduated from the Mount Sinai School of Medicine in 1999. Dr. Davidson also attended Mount...

Dr. Michael Dudley has over 30 years of experience in antiinfective drug research and development, with experience in the discovery, preclinical and clinical stages in both academia and industry. He has overseen the development and regulatory approval of 3 antibiotics, most recently a...

Barry Eisenstein received his MD from Columbia University followed by training in Internal Medicine and Infectious Diseases at the University of North Carolina. He has spent his career in academia and industry, serving as chief of the ID division at the University of Texas Health Sciences...

Debra A. Goff, Pharm.D., FCCP, is Infectious Disease Specialist and founding member of the Antimicrobial Stewardship Program at The Ohio State University Wexner Medical Center (OSUWMC). She is the past-Director of the Infectious Diseases Residency program at The Ohio State University Medical Center ...

Dr. Hermsen is the Head of Global Antimicrobial Stewardship in Global Population Health at Merck & Co. and an Adjunct Associate Professor at the University of Nebraska Medical Center, Colleges of Pharmacy and Medicine, in Omaha, Nebraska.  Dr. Hermsen received her Doctor of Pharmacy degree from ...

Dr. Houchens is the Chief of the Antibacterials Branch within the CBRN Division of BARDA and has been with BARDA since April 2012.  His primary focus is building and managing a diverse portfolio of novel therapeutics targeting both biowarfare agents and the global threat of antimicrobial...

Dr Peter Jackson is Executive Director of the AMR Centre – a UK public-private partnership focused on antimicrobial resistance R&D, and an alliance member of the transatlantic CARB-X initiative.  An experienced life sciences entrepreneur, Dr Jackson is the founder of six life sciences ventures...

Sanjay Kakkar is a biotech entrepreneur and executive with over 20 years’ experience in multinational corporations, early stage and high growth enterprises. He has a track record of building innovative companies in the life sciences/healthcare industries and the development of novel technologies...

Patrick Keenan is the Managing Director of Prevail Partners, LLC, a life sciences investment firm focused on innovative clinical stage therapeutic, medical device and diagnostics companies. During his nine-year tenure, Prevail Partners has invested in over 30 private and public companies.  These...

Dr. Lawrence D. Kerr (Larry) is the Director of Pandemic and Emerging Threats within the Office of Global Affairs at the Department of Health and Human Services (HHS).  Dr. Kerr leads and manages the Office overseeing a broad policy portfolio including the Global Health Security Agenda...

Barbara Kerstiëns, MD, MPH is the Deputy Head of Unit in the unit responsible for infectious diseases and public health in the Health Directorate of the Directorate-General for Research and Innovation at the European Commission. She has a long experience in international public health, working for...

Dr. Eili Klein is a fellow at the Center for Disease Dynamics, Economics & Policy, an Assistant Professor in the Department of Emergency Medicine in the Johns Hopkins School of Medicine, and an Assistant Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public ...

A board-certified internist and a Fulbright scholar, Dr. Knecht has developed insights into the health care industry through experiences in pharmaceutical entrepreneurship, life science strategy consulting, patient care and population health research. Dr. Knecht currently serves as Vice President...

Jane Knisely is a Program Officer in the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease, NIH, where she oversees scientific programs related to antimicrobial resistance and antibacterial drug...

Jill Massey, PharmD, MBA is the Senior Vice President for Melinta Therapeutics, Inc with responsibility for the development and leadership of the Melinta Antimicrobial Resistance Program and all Medical Affairs initiatives.  She is a senior Medical Affairs Executive with proven success in affecting ...

Tyler Merkeley, MS, MBA, PMP is the co-founder of CARB-X and serves as the Biomedical Advanced Research and Development Authority’s (BARDA) CARB-X Program Manager. Mr. Merkeley joined the Department of Health and Human Services (HHS), BARDA in 2009 as a Health Scientist in an effort to accelerate...

Board-certified Clinical Microbiologist; before coming to Merck was the Director of Clinical Microbiology at Beth Israel Medical Center in NYC. At Merck is in the Basic Research Discovery and Development group and is  part of Merck’s Antimicrobial Susceptibility Testing Development Team.

Dr. Manos Perros is President and Chief Executive Officer of Entasis Therapeutics.  Manos was central to the establishment of Entasis Therapeutics, and led talks with AstraZeneca that resulted in the creation of the new company in 2015.  Manos was Vice President of the Innovative medicines and...

Josh co-leads SV’s US Biotech practice out of SV’s Boston office. He is also responsible for SV’s venture-creation activities, including the activities of SV’s incubator, Brahma Discovery. He is a member of the investment committee of the Dementia Discovery Fund. Josh is a highly-regarded life...

Dr. Mike Salter works for AB Agri as an innovation scientist seeking out new ideas and potential product solutions for all 6 AB Agri business units. In this role he engages with Academic Institutions, Research Institutes and other businesses, usually SMEs. Mike is particularly engaged in...

Robert Sambursky, MD is one of the original founders of RPS Diagnostics, and has served various roles including Chief Executive Officer from July 2012 until June 2017, President since 2010, and Chief Medical Officer since 2008. He is an inaugural member of both the Leadership Team and Board of...

Monika Schneider is a Research Associate within the biomedical innovation team at the Duke-Margolis Center for Health Policy. Her work focuses on incentives for antimicrobial product development, value-based reimbursement policy, and payment reform for medical products.Prior to...

Dr. Ed Septimus received his medical degree from Baylor College of Medicine in Houston in 1972.  Dr. Septimus went on to complete his postgraduate training in internal medicine and infectious diseases at Baylor College of Medicine in Houston. Dr. Ed Septimus is board certified in both internal...

Dr. Ribhi Shawar currently serves as the Branch Chief at the Division of Microbiology in the Office of In vitro Diagnostic and Radiological Health (OIR) at the Center for Devices and Radiological Health (CDRH) at FDA where he specializes in the area of antimicrobial susceptibility testing and...

Dr. Sibbel recently retired from nearly 39 years of mixed veterinary practice and multiple animal health company leadership roles. Most recently, he was Executive Director of Technical Services for Merck Animal Health in the US Food Animal Business Unit. In his latest role, he was responsible for...

Jennifer Townsend, MD is an Assistant Professor in Infectious Disease (ID) at Johns Hopkins University. She directs the Antimicrobial Stewardship Program at Johns Hopkins Bayview Medical Center as well as the OPAT program for patients discharged on parenteral antibiotics. She strives to reduce...

Brian Tse is currently serving as a Health Scientist at the Biomedical Advanced Research & Development Authority (BARDA), the lead organization in the U.S. Dept. of Health & Human Services for the advanced development and acquisition of medical countermeasures for public health emergencies...

David Visi is a senior associate on Pew’s antibiotic resistance project, focusing on research and policies to help spur the discovery and development of antibiotics. Prior to joining Pew, Visi was a congressional science fellow in the House of Representatives working on agriculture and health...

Dan Wechsler joined Melinta as President and Chief Executive Officer in November 2017 and is a seasoned pharmaceutical executive with more than 25 years of healthcare experience across multiple companies and geographies, and a proven record of strategic, operational and commercial success. His...

Mr. Wise became Chief Executive Officer, and joined the Company’s Board of Directors, in January 2018. Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer. Prior to Achaogen, Mr. Wise spent 13 years at...

Founder and CEO of Forge Therapeutics Inc with over 15+ years of start-up experience in business leadership roles at Arcturus Therapeutics (private), Regulus Therapeutics (NASDAQ:RGLS), Alnylam Pharmaceuticals (NASDAQ:ALNY).  Successfully driven company growth through strategic...